One of these compounds, adenosine 5’-monophosphate (A5MP), selectively inhibited the growth of BRCA1-deficient HCC1937 breast carcinoma cells (adenosine was added to the cells and phosphorylated intracellular), even though that RAD52 does not have a nucleotide binding site. This evidence concerns the gene RAD52 and breast carcinoma.